Food

 

IDO Inhibitors - A Pipeline Analysis Report - New Market Report



03.03.2018 18:05:31 - Recently published research from TechNavio, "IDO Inhibitors - A Pipeline Analysis Report", is now available at Fast Market Research

(live-PR.com) - IDO inhibitors: An insight
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
A few large pharmaceutical

 

companies are investing billions of dollars through multiple collaboration agreements for the R&D for IDO inhibitors. The synergistic effects of IDO inhibitors with chemotherapy together may create a new opportunity for vaccines and immunotherapy. The combination of IDO inhibitors with vaccines can redefine the cancer treatment in coming years if everything goes in the right direction as per the initial results.

Full Report Details at
- fastmr.com/products/1310610-ido-inhibitors-pipel ..

Covered in this report
The report covers the present scenario and the growth prospects of the IDO inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's IDO Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

* Pfizer
* Bristol-Myers Squibb
* Kyowa Hakko Kirin

Key questions answered in this report

* How will the market evolve during the forecast period?
* What are the major parameters impacting the market?
* What are the key market trends?
* What are the challenges to market growth?
* Who are the key companies in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Pfizer, Bristol-Myers Squibb, Kyowa Hakko Kirin

Partial Table of Contents:

Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: IDO INHIBITORS: AN INSIGHT
- Introduction
PART 05: REGULATORY FRAMEWORK
- US
- Europe
- Japan
- Australia
- China
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Late-stage molecule (Phase III)
- Mid-stage molecule (Phase II)
- Early-stage molecules (Phase I/II and I)
- Pre-clinical and discovery stage molecules
- Inactive molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT BY THERAPY
- Therapeutic assessment based on therapy
PART 10: THERAPEUTIC ASSESSMENT BY ROA
- Therapeutic assessment based on RoA
PART 11: THERAPEUTIC ASSESSMENT BY MOLECULE TYPE
- Therapeutic assessment based on molecule type
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
List of Exhibits 
Exhibit 01: Overview of collaboration agreements in global IDO inhibitors market 2017
Exhibit 02: Drug approval process by US FDA
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules by vendors
Exhibit 05: Pipeline molecules by numbers
Exhibit 06: Pipeline molecules by percentage
Exhibit 07: Overview: Epacadostat
Exhibit 08: Clinical trials description of epacadostat
Exhibit 09: Overview: Indoximod
Exhibit 10: Clinical trials description of indoximod
Exhibit 11: Overview: BMS-986205
Exhibit 12: Clinical trials description of BMS-986205
Exhibit 13: Overview: Navoximod
Exhibit 14: Clinical trials description of navoximod
Exhibit 15: Overview: PF 06840003
Exhibit 16: Clinical trials description of PF-06840003
Exhibit 17: Overview: KHK2455 oral
Exhibit 18: Clinical trials description of KHK2455 oral
Exhibit 19: Overview: NLG802
Exhibit 20: Clinical trials description of NLG802
Exhibit 21: Overview: IDO inhibitor
Exhibit 22: Overview: GBV1012
Exhibit 23: Overview: GBV1028
Exhibit 24: Overview: RG70099
Exhibit 25: Overview: IDO inhibitor
Exhibit 26: Overview: IDO1 inhibitor
Exhibit 27: Overview: Dual IDO1/TDO inhibitor
Exhibit 28: Overview: IDO-1 inhibitor
Exhibit 29: Overview: dCellVax
Exhibit 30: Overview: IDO1 Inhibitor
Exhibit 31: Overview: Covalent IDO inhibitors

Full Table of Contents is available at:
-- fastmr.com/products/1310610-ido-inhibitors-pipel ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)


Author:
Bill Thompson
e-mail
Web: http://www.fastmr.com
Phone: 1.413.485.7001


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us